VisionPoint Advisory Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$896K Buy
6,013
+31
+0.5% +$4.35K 0.14% 158
2026
Q2
$756K Buy
5,982
+1,216
+26% +$160K 0.12% 191
2026
Q1
$664K Sell
4,766
-1,761
-27% -$247K 0.13% 187
2025
Q4
$801K Buy
6,527
+1,672
+34% +$203K 0.16% 151
2025
Q3
$539K Buy
4,855
+491
+11% +$55.8K 0.11% 198
2025
Q2
$484K Buy
+4,364
New +$464K 0.11% 191
2024
Q2
– Sell
-29
Closed -$2.12K – 841
2024
Q1
$2.12K Hold
29
– – ﹤0.01% 675
2023
Q4
$2.35K Buy
+29
New +$2.26K ﹤0.01% 599

Other funds holding GILD

VisionPoint Advisory Group's GILD Position: Q3 2026 in Review

VisionPoint Advisory Group increased its Gilead Sciences (GILD) stake by 0.52% in Q3 2026, buying an estimated $4.35K and bringing the position to 6,013 shares worth $896K. The position accounts for 0.14% of the portfolio, ranked #158.

VisionPoint Advisory Group first reported a position in GILD in Q4 2023 and has held it in 8 quarters since. 2,330 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • VisionPoint Advisory Group held 6,013 shares of Gilead Sciences worth $896K as of Q3 2026.
  • VisionPoint Advisory Group bought 31 Gilead Sciences shares in Q3 2026, an estimated $4.35K.
  • Gilead Sciences made up 0.14% of VisionPoint Advisory Group's portfolio in Q3 2026, its #158 holding.
  • VisionPoint Advisory Group first reported a position in Gilead Sciences in Q4 2023 and has held it in 8 quarters since.
  • 2,330 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.